Patients Taking Ozempic Are Up to 70 Percent Less Likely to Develop Alzheimer’s, Research Finds

The active ingredient in Ozempic and Wegovy has once again proven to have health effects far outside of weight loss in a huge analysis linking it to lowered Alzheimer's disease risk.

Looking at more than a million patient records, researchers at Case Western Reserve School of Medicine discovered that diabetic seniors on semaglutide were far less likely to develop Alzheimer's than their counterparts who took other diabetes medications.

This effect was most stark when comparing semaglutide to the old-school diabetes injectable insulin, with patients on semaglutide showing a whopping 70 percent lowered risk of Alzheimer's.

In the study, published in the journal Alzheimer's and Dementia, the Case Western researchers led by biomedical informatics expert Rong Xu used medical records from patients over the age of 60 with Type 2 diabetes to run a randomized statistical analysis that mimics a clinical trial.